Article Information
PubMed
Print ISSN
Online ISSN
History
- Received March 16, 2006
- Accepted May 3, 2006
- Published online July 18, 2006.
Article Versions
- Earlier version (May 3, 2006 - 12:44).
- You are viewing the most recent version of this article.
Copyright & Usage
The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Ning Gao,
- Lora Kramer,
- Mohamed Rahmani,
- Paul Dent and
- Steven Grant
- Departments of Medicine (N.G., L.K., M.R., S.G.), Biochemistry (S.G., P.D.), and Pharmacology, Virginia Commonwealth University and Massey Cancer Center, Richmond, Virginia (S.G.)
- Address correspondence to:
Dr. Steven Grant, Division of Hematology/Oncology, MCV Station Box 230, Virginia Commonwealth University/Medical College of Virginia, Richmond, VA 23298. E-mail: stgrant{at}hsc.vcu.edu
Statistics from Altmetric.com
Article usage
In this issue
The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 through a Transcriptional Mechanism
